University Hospitals of Cleveland

The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.

Rosalind Franklin University of Medicine and Science

University Hospitals Cleveland Medical Center

Uniformed Services University of the Health Sciences, an Institution of Higher Learning Within the Department of Defense

George Gorodeski

Wen Fu

Ying-Hong Feng

Xin Li

Judith Ann Potashkin

Bentley Cheatham

A relationship between cancer and ribonucleic acid (RNA) regulation is described by determining intracellular levels of niRN A regulators. Generally, mRNA levels are decreased in cancer cells that may be a reflection of either reduced mRNA expression and/or increased mRNA degradation. miRNAs are identified that hybridize to an mRNA that are suspected to mediate intracellular mRNA steady state levels. Alternatively, ribonucleic acid binding protein (RBP) levels may also mediate intracellular mRNA steady state levels. In particular, this invention demonstrates an effective clinical management strategy for uterine cell cancers may be implemented by taking advantage of an exemplary relationship between P2XmRNA and miRNAs including, but not limited to, miR-186 and/or miR-150.

Screening, diagnosing, treating and prognosis of pathophysiologic status by RNA regulation

The present invention demonstrates that P2Xreceptor induced apoptosis may be specific for cancerous cells. Treatment with the P2Xligand BzATP, increased cellular apoptosis with no associated inflammatory changes or abnormal skin or systemic effects. In mice treated with DMBA/TPA, BzATP decreased papilloma skin formation. BzATP also induced involution of developed papillomas and stimulated apoptosis in keratinocytes outgrowing at the base of developed papillomas. These data show that (a) P2Xregulates apoptosis of epidermal cells; (b) in vivo, local administration of a drug that activates the P2Xreceptor can inhibit development and progression of epidermal premalignant lesions.

[object Object]

Methods/reagents for detecting and/or treating cancers or potential cancers are disclosed. In one embodiment, methods and reagents for detecting truncated forms of P2Xprotein in cells are described. In one embodiment, methods and reagents for increasing the amount and/or activity of full-length P2Xin cells are described. In one embodiment, methods and reagents for decreasing the amount and/or activity of truncated P2Xin cells are described.

Truncated proteins as cancer markers

Growing community of inventors

Beachwood, OH, United States of America

George Gorodeski